Synojoynt (1% sodium hyaluronate) / Hanmi, Arthrex - LARVOL DELTA

Connections between cohesion and properties that related to safety and effectiveness of the hyaluronic acid dermal fillers: A comparative study of the cohesive and non-cohesive gels. (PubMed, Skin Res Technol) - "Hyalumatrix is a rare HA filler product to possess good cohesion and intermediate G' simultaneously. More clinical practice is needed to verify the connection between the cohesion of Hyalumatrix and the clinical performance."

Journal • Aesthetic Medicine

Hanmi re-launches osteoarthritis injection treatment in US (Korea Biomedical Review) - "Hanmi Pharmaceutical said that it has started marketing SynoJoynt, an osteoarthritis injection treatment, with Arthrex, a global medical device company, in the U.S....After FDA approval, Hanmi Pharm entered the U.S. market by signing a contract with Teva. However, to further accelerate SynoJoynt success, the company ended its partnership with Teva and joined hands with Arthrex, which has strength in orthopedic surgery."

Launch US • Licensing / partnership • CNS Disorders • Osteoarthritis • Pain

Teva launches 1% sodium hyaluronate in U.S. (SeekingAlpha) - "Teva Pharmaceutical Industries...commences the U.S. commercial launch of 1% sodium hyaluronate for the treatment of pain associated with osteoarthritis of the knee in patients who have failed to adequately respond to non-drug therapy and simple painkillers (e.g., acetaminophen)."

Launch US